Experimental drug promising to bring down bad cholesterol by up to 69% completes early stage trial

The potential breakthrough medicine developed by US-based biotechnology firm Verve Therapeutics is a novel, in vivo (delivered directly into the body), base editing medicine that permanently turns off the PCSK9 gene (a protein that plays a role in re…